NeuroVive receives KL1333 clinical trial regulatory approval
Lund, Sweden, 10 October 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that it has received approval of its clinical trial application concerning a planned phase I KL1333 study in patients and healthy volunteers from the UK regulatory authority, Medicines and Healthcare products Regulatory Agency (MHRA).KL1333 is a first-in-class NAD+modulator in clinical development for chronic oral treatment in genetic mitochondrial diseases. The primary purpose of the study is to investigate the pharmacokinetics, safety and tolerability of KL1333 in healthy